Intranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against influenza viruses

Molecular Therapy

Volumn 19, Issue 3, 2011, Pages 602-611

  Torrieri Dramard, Lea ^a,b,c,d   Lambrecht, Bénédicte ^e   Ferreira, Helena Lage ^e   Van Den Berg, Thierry ^e   Klatzmann, David ^a,b,c,d   Bellier, Bertrand ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b CNRS   (France)

^c Unit of Dermatology   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e VETERINARY AND AGROCHEMICAL RESEARCH CENTRE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; IMMUNOGLOBULIN A ANTIBODY; INFLUENZA VIRUS HEMAGGLUTININ; POLYETHYLENEIMINE;

2009 H1N1 INFLUENZA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PROTECTION; DNA IMMUNIZATION; DRUG POTENCY; EMBRYO; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; INFLUENZA A (H5N1); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEOTIDE SEQUENCE; VIRUS IMMUNITY;

ORTHOMYXOVIRIDAE;

EID: 79952190213     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.222     Document Type: Article

References (45)

1. Neutra, MR and Kozlowski, PA (2006). Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6: 148-158. (Pubitemid 43361590)
2. Hasegawa, H, Ichinohe, T, Tamura, S and Kurata, T (2007). Development of a mucosal vaccine for infuenza viruses: preparation for a potential infuenza pandemic. Expert Rev Vaccines 6: 193-201. (Pubitemid 46607455)
3. Hutchings, AB, Helander, A, Silvey, KJ, Chandran, K, Lucas, WT, Nibert, ML et al. (2004). Secretory immunoglobulin A antibodies against the sigma1 outer capsid protein of reovirus type 1 Lang prevent infection of mouse Peyer's patches. J Virol 78: 947-957. (Pubitemid 38067616)
4. Moldoveanu, Z, Clements, ML, Prince, SJ, Murphy, BR and Mestecky, J (1995). Human immune responses to infuenza virus vaccines administered by systemic or mucosal routes. Vaccine 13: 1006-1012.
5. Belshe, RB, Nichol, KL, Black, SB, Shinefeld, H, Cordova, J, Walker, R et al. (2004). Safety, effcacy, and effectiveness of live, attenuated, cold-adapted infuenza vaccine in an indicated population aged 5-49 years. Clin Infect Dis 39: 920-927. (Pubitemid 39313444)
6. Nichol, KL, Mendelman, PM, Mallon, KP, Jackson, LA, Gorse, GJ, Belshe, RB et al. (1999). Effectiveness of live, attenuated intranasal infuenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 282: 137-144. (Pubitemid 29323803)
7. Ichinohe, T, Ainai, A, Tashiro, M, Sata, T and Hasegawa, H (2009). PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 infuenza virus variants. Vaccine 27: 6276-6279.
8. Xiaowen, Z, Qinghua, Y, Xiaofei, Z and Qian, Y (2009). Co-administration of inactivated avian infuenza virus with CpG or rIL-2 strongly enhances the local immune response after intranasal immunization in chicken. Vaccine 27: 5628-5632.
9. Durrer, P, Glück, U, Spyr, C, Lang, AB, Zurbriggen, R, Herzog, C et al. (2003). Mucosal antibody response induced with a nasal virosome-based infuenza vaccine. Vaccine 21: 4328-4334. (Pubitemid 37130275)
10. Coulter, A, Harris, R, Davis, R, Drane, D, Cox, J, Ryan, D et al. (2003). Intranasal vaccination with ISCOMATRIX adjuvanted infuenza vaccine. Vaccine 21: 946-949. (Pubitemid 36126429)
11. Sanders, MT, Deliyannis, G, Pearse, MJ, McNamara, MK and Brown, LE (2009). Single dose intranasal immunization with ISCOMATRIX vaccines to elicit antibody-mediated clearance of infuenza virus requires delivery to the lower respiratory tract. Vaccine 27: 2475-2482.
12. Bhattacharya, P, Grimme, S, Ganesh, B, Gopisetty, A, Sheng, JR, Martinez, O et al. (2010). Nanodisc-incorporated hemagglutinin provides protective immunity against infuenza virus infection. J Virol 84: 361-371.
13. Webster, RG (1999). Potential advantages of DNA immunization for infuenza epidemic and pandemic planning. Clin Infect Dis 28: 225-229. (Pubitemid 29241204)
14. Zheng, L, Wang, F, Yang, Z, Chen, J, Chang, H and Chen, Z (2009). A single immunization with HA DNA vaccine by electroporation induces early protection against H5N1 avian infuenza virus challenge in mice. BMC Infect Dis 9: 17.
15. Chen, Q, Kuang, H, Wang, H, Fang, F, Yang, Z, Zhang, Z et al. (2009). Comparing the ability of a series of viral protein-expressing plasmid DNAs to protect against H5N1 infuenza virus. Virus Genes 38: 30-38.
16. Rao, S, Kong, WP, Wei, CJ, Yang, ZY, Nason, M, Styles, D et al. (2008). Multivalent HA DNA vaccination protects against highly pathogenic H5N1 avian infuenza infection in chickens and mice. PLoS ONE 3: e2432.
17. Boussif, O, Lezoualc'h, F, Zanta, MA, Mergny, MD, Scherman, D, Demeneix, B et al. (1995). A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 92: 7297-7301.
18. Davies, LA, McLachlan, G, Sumner-Jones, SG, Ferguson, D, Baker, A, Tennant, P et al. (2008). Enhanced lung gene expression after aerosol delivery of concentrated pDNA/PEI complexes. Mol Ther 16: 1283-1290. (Pubitemid 351866060)
19. Roos, AK, Eriksson, F, Timmons, JA, Gerhardt, J, Nyman, U, Gudmundsdotter, L et al. (2009). Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS ONE 4: e7226.
20. Garigliany, MM, Habyarimana, A, Lambrecht, B, Van de Paar, E, Cornet, A, Van den Berg, T et al (2010). Infuenza A strain-dependent pathogenesis in fatal H1N1 and H5N1 subtype infections of mice. Emerg Infect Dis 16: 595-603.
21. Greenbaum, E, Engelhard, D, Levy, R, Schlezinger, M, Morag, A and Zakay-Rones, Z (2004). Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-infuenza vaccine. Vaccine 22: 2566-2577. (Pubitemid 38757360)
22. Muszkat, M, Greenbaum, E, Ben-Yehuda, A, Oster, M, Yeu'l, E, Heimann, S et al. (2003). Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated infuenza vaccine. Vaccine 21: 1180-1186. (Pubitemid 36139947)
23. Hagenaars, N, Mastrobattista, E, Glansbeek, H, Heldens, J, van den Bosch, H, Schijns, V et al. (2008). Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived infuenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model. Vaccine 26: 6555-6563.
24. Forde, GM (2005). Rapid-response vaccines-does DNA offer a solution? Nat Biotechnol 23: 1059-1062. (Pubitemid 41486383)
25. Salonius, K, Simard, N, Harland, R and Ulmer, JB (2007). The road to licensure of a DNA vaccine. Curr Opin Investig Drugs 8: 635-641. (Pubitemid 47205247)
26. Densmore, CL, Orson, FM, Xu, B, Kinsey, BM, Waldrep, JC, Hua, P et al. (2000). Aerosol delivery of robust polyethyleneimine-DNA complexes for gene therapy and genetic immunization. Mol Ther 1: 180-188.
27. Luxembourg, A, Evans, CF and Hannaman, D (2007). Electroporation-based DNA immunisation: translation to the clinic. Expert Opin Biol Ther 7: 1647-1664. (Pubitemid 350161649)
28. Regnström, K, Ragnarsson, EG, Köping-Höggård, M, Torstensson, E, Nyblom, H and Artursson, P (2003). PEI - a potent, but not harmless, mucosal immuno-stimulator of mixed T-helper cell response and FasL-mediated cell death in mice. Gene Ther 10: 1575-1583. (Pubitemid 37063263)
29. + T cells. Blood 107: 4781-4789. (Pubitemid 43882629)
30. Darrah, PA, Patel, DT, De Luca, PM, Lindsay, RW, Davey, DF, Flynn, BJ et al. (2007). Multifunctional TH1 cells defne a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13: 843-850. (Pubitemid 47038186)
31. + T cells is refected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 204: 2473-2485. (Pubitemid 47529331)
32. Ciuffreda, D, Comte, D, Cavassini, M, Giostra, E, Bühler, L, Perruchoud, M et al. (2008). Polyfunctional HCV-specifc T-cell responses are associated with effective control of HCV replication. Eur J Immunol 38: 2665-2677.
33. Klavinskis, LS, Barnfeld, C, Gao, L and Parker, S (1999). Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts. J Immunol 162: 254-262. (Pubitemid 29018927)
34. Huang, X, Xu, J, Qiu, C, Ren, L, Liu, L, Wan, Y et al. (2007). Mucosal priming with PEI/DNA complex and systemic boosting with recombinant TianTan vaccinia stimulate vigorous mucosal and systemic immune responses. Vaccine 25: 2620-2629. (Pubitemid 46400929)
35. Mestecky, J (1987). The common mucosal immune system and current strategies for induction of immune responses in external secretions. J Clin Immunol 7: 265-276. (Pubitemid 17146794)
36. Brandtzaeg, P (2007). Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25: 5467-5484. (Pubitemid 47031365)
37. Tamura, S, Funato, H, Hirabayashi, Y, Kikuta, K, Suzuki, Y, Nagamine, T et al. (1990). Functional role of respiratory tract haemagglutinin-specifc IgA antibodies in protection against infuenza. Vaccine 8: 479-485. (Pubitemid 20332858)
38. Chen, MW, Cheng, TJ, Huang, Y, Jan, JT, Ma, SH, Yu, AL et al. (2008). A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 infuenza viruses. Proc Natl Acad Sci USA 105: 13538-13543.
39. Laddy, DJ, Yan, J, Corbitt, N, Kobasa, D, Kobinger, GP and Weiner, DB (2007). Immunogenicity of novel consensus-based DNA vaccines against avian infuenza. Vaccine 25: 2984-2989. (Pubitemid 46482729)
40. Chen, Z, Kadowaki, S, Hagiwara, Y, Yoshikawa, T, Matsuo, K, Kurata, T et al. (2000). Cross-protection against a lethal infuenza virus infection by DNA vaccine to neuraminidase. Vaccine 18: 3214-3222. (Pubitemid 30408197)
41. Sandbulte, MR, Jimenez, GS, Boon, AC, Smith, LR, Treanor, JJ and Webby, RJ (2007). Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 4: e59.
42. Bellier, B, Huret, C, Miyalou, M, Desjardins, D, Frenkiel, M P, Despres, P et al. (2009). DNA vaccines expressing retrovirus-like particles are effcient immunogens to induce neutralizing antibodies. Vaccine 27: 5772-5780.
43. Bartosch, B, Bukh, J, Meunier, JC, Granier, C, Engle, RE, Blackwelder, WC et al. (2003). In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci USA 100: 14199-14204. (Pubitemid 37499214)
44. Steensels, M, Bublot, M, Van Borm, S, De Vriese, J, Lambrecht, B, Richard-Mazet, A et al. (2009). Prime-boost vaccination with a fowlpox vector and an inactivated avian infuenza vaccine is highly immunogenic in Pekin ducks challenged with Asian H5N1 HPAI. Vaccine 27: 646-654.
45. Van Borm, S, Steensels, M, Ferreira, HL, Boschmans, M, De Vriese, J, Lambrecht, B et al. (2007). A universal avian endogenous real-time reverse transcriptase-polymerase chain reaction control and its application to avian infuenza diagnosis and quantifcation. Avian Dis 51(1 Suppl): 213-220. (Pubitemid 46671282)